期刊： ADVANCES IN THERAPY, 2023; 40 (3)
Introduction CMAB008 is a monoclonal antibody developed as a biosimilar to infliximab (Remicade((R)), Janssen). The pharmacokinetic characteristics of......
期刊： ADVANCES IN THERAPY, 2023; 40 (4)
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs with potent glucose-lowering activity. Additionally, some GLP-1 RAs have de......
期刊： ADVANCES IN THERAPY, 2023; 40 (10)
IntroductionSugemalimab is the first China-developed programmed death-ligand 1 inhibitor that has proved to be effective as a first-line treatment for......
期刊： ADVANCES IN THERAPY, 2023; 40 (11)
Introduction: Healthcare systems are looking to reduce their carbon impact. Short-acting beta 2-agonist (SABA) overuse (>= 3 canisters/year) is com......
期刊： ADVANCES IN THERAPY, 2023; 40 (5)
IntroductionRetinitis pigmentosa (RP) is an inherited progressive disease, characterized by a loss of photoreceptors, and is the second leading cause ......
期刊： ADVANCES IN THERAPY, 2023; 40 (4)
Introduction: Nintedanib is recommended for the treatment of idiopathic pulmonary fibrosis (IPF); however, treatment discontinuation due to adverse ev......
期刊： ADVANCES IN THERAPY, 2023; 40 (4)
Introduction: The efficacy of cemiplimab in recurrent cervical cancer has been demonstrated in the clinical trial EMPOWER-Cervical 1. However, its hig......
期刊： ADVANCES IN THERAPY, 2023; 40 (10)
IntroductionEnhanced monofocal intraocular lenses (IOLs) represent a new type of lens, which should lead to a very good distance vision similar to mon......
期刊： ADVANCES IN THERAPY, 2023; ()
IntroductionThe European Medicines Agency restored aprotinin (APR) use for preventing blood loss in patients undergoing isolated coronary artery bypas......
期刊： ADVANCES IN THERAPY, 2023; 40 (4)
Introduction: This study evaluated the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib plus programmed death (P......
期刊： ADVANCES IN THERAPY, 2023; 40 (6)
IntroductionBreast cancer in older women tends to have more favourable biology, compared to younger women. Androgen receptor (AR) is significant for b......
期刊： ADVANCES IN THERAPY, 2023; 40 (8)
Introduction: As new glucagon-like peptide 1 receptor agonist (GLP-1 RA) formulations are available, the aim of this study was to understand dulagluti......
期刊： ADVANCES IN THERAPY, 2023; ()
IntroductionEthnicity differences are an important determinant in the clinical manifestation of Parkinson's disease (PD), but they are not yet widely ......
